Agreement - July 30, 2014
AstraZeneca signs deal with Almirall
AstraZeneca agrees strategic transaction with Almirall in respiratory disease. AstraZeneca has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. Also, AstraZeneca has agreed to make various sales-related payments. Upon completion […]
Collaboration - July 29, 2014
AstraZeneca in new collaborations
AstraZeneca has entered a new collaboration with Dutch Qiagen and a partnership with Roche. The company has entered into a collaboration with Netherlands-based Qiagen to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks […]
Uncategorized - July 27, 2014
AstraZeneca presents design for new R&D centre
AstraZeneca has revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. “We are very excited to be able to reveal the plans for our new site in Cambridge today. Our aim is to create an open, welcoming and vibrant centre that will inspire our teams and partners […]
Acquisition - July 26, 2014
Elekta acquires Mesi Medikal
Elekta has acquired the Turkish distributor of radiation oncology solutions Mesi Medikal A.S. Signing and closing of the acquisition took place on July 24, 2014. Mesi Medikal will change its name to Elekta and will be a fully owned company. The acquisition of Mesi Medikal is expected to add approximately 0.3% to Elekta’s revenues on an annual basis. The […]
Clinical Trials - July 25, 2014
CLS gets green light for new study
Clinical Laserthermia Systems has been given another approval by the Ethical Review Board for a clinical study in Europe. The company, which develops and markets Interstitial Laser Thermo Therapy, a polyclinical hyperthermic (heat-induced) cancer immunotherapy for gentle and effective treatment of solid cancer tumors, has received final approval for a previously communicated study in France. The study in France regards skin cancer, while […]
Uncategorized - July 23, 2014
Supermaterial gives rejected drugs a new chance
Uppsala University researchers show that the new material Upsalite has great potential for development of new formulations of rejected drugs. Upsalite, presented in 2013, had the highest surface area ever measures for an alkali earth metal carbonate; 800 square meters per gram. According to a new study published in International Journal of Pharmaceutics, the extremely porous magnesium […]
